U.S. Markets close in 2 hrs 54 mins
  • S&P 500

    +41.39 (+0.96%)
  • Dow 30

    +117.20 (+0.34%)
  • Nasdaq

    +203.61 (+1.52%)
  • Russell 2000

    -1.98 (-0.10%)
  • Crude Oil

    +0.40 (+0.46%)
  • Gold

    -10.30 (-0.57%)
  • Silver

    -0.47 (-2.08%)

    +0.0010 (+0.0893%)
  • 10-Yr Bond

    -0.0250 (-1.38%)
  • Vix

    -0.37 (-1.21%)

    +0.0011 (+0.0817%)

    -0.0220 (-0.0191%)

    +553.59 (+1.52%)
  • CMC Crypto 200

    -2.78 (-0.33%)
  • FTSE 100

    -88.24 (-1.17%)
  • Nikkei 225

    +547.04 (+2.09%)

ATNX DEADLINE TODAY: HAGENS BERMAN, National Trial Attorneys, Alerts Athenex (ATNX) Investors to Lead Plaintiff Dead in Securities Class Action, Advises Investors with Losses to Contact the Firm Immediately

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ATNX

SAN FRANCISCO, CA / ACCESSWIRE / May 3, 2021 / Hagens Berman urges Athenex, Inc. (NASDAQ:ATNX) investors with significant losses to submit your losses now.

Class Period: Aug. 7, 2019 - Feb. 26, 2021
Lead Plaintiff Deadline: May 3, 2021
Contact An Attorney Now:ATNX@hbsslaw.com

Athenex, Inc. (NASDAQ:ATNX) Securities Class Action:

The Complaint alleges that throughout the Class Period, Defendants made false statements and omissions about its flagship drug candidate, an oral paclitaxel and encequidar for the treatment of metastatic breast cancer.

Specifically, Defendants misrepresented and concealed that: (i) the data included in the Oral Paclitaxel plus Encequidar New Drug Application presented a safety risk to patients; (ii) there was uncertainty over the results of the primary endpoint of objective response rate (ORR), which might have introduced unmeasured bias and influence on the blinded independent central review (BICR); (iii) the Company's Phase 3 study did not include a representative population; and (iv) as a result, it was foreseeable that the FDA would not approve the Company's NDA in its current form.

On Mar. 1, 2021, the market learned the truth when Athenex announced it received the FDA's complete response letter ("CRL") to the NDA for oral paclitaxel plus encequidar. In the CRL, the FDA cited safety risks to patients in terms of an increase in neutropenia-related sequalae. The CRL also cited uncertainty over the results of the primary endpoint of the ORR at week 19, which might have introduced unmeasured bias and influence on the BICR. The FDA further recommended that "Athenex conduct a new adequate and well-conducted clinical trial in a patient population with metastatic breast cancer representative of the population in the U.S."

On this news, shares of Athenex stock fell approximately 55% in one day.

"We're focused on investors' losses and proving Athenex intentionally misled investors about its leading drug candidate," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are an Athenex investor and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Athenex should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email ATNX@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

View source version on accesswire.com: